A PYMNTS Company

EU: Takeda considers selling experimental drug to win EU approval

By  |  October 28, 2018

Pharmaceutical company Takeda is talking with the European Commission about selling an experimental inflammatory bowel disease drug to help close its US$62 billion takeover of Shire.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    In a statement released Friday, October 26, Takeda stated that it has been in discussions with the EC about divesting SHP647, which is in the final stages of experimental testing for the treatment of two gastrointestinal disorders: Crohn’s disease and ulcerative colitis.

    This specific drug has come to attention since Takeda already markets the drug Entyvio for those conditions. In just 2018, Entyvio sales brought Takeda US$1.8 billion.

    The company claims that there are no other pharmaceuticals being discussed and that it doesn’t see any delays affecting the EC’s review being finished by its November 6 deadline.

    The deal has already won approval from China, the US Federal Trade Commission, Brazil and Japan, making Europe the final major market that needs to sign off.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.